Two studies published in the Journal of Alzheimer’s Disease indicate that some of the pathologic changes associated with Alzheimer’s disease in older individuals are not apparent in young people who carry the apolipoprotein (APOE) genetic risk factor for developing the disease. In the first study, no differences were found in hippocampal volume or asymmetry between cognitively normal adolescent carriers and non-carriers of the ApoE ɛ4 or ɛ2 allelles. The second study reports no differences in plasma concentrations of amyloid-β peptides among young adult ɛ4, ɛ3 or ɛ2 carriers.
Carriers of the apolipoprotein (ApoE) ɛ4 allele are at greater risk for developing late-onset Alzheimer’s disease (AD), develop AD at an earlier age, and experience a more severe cognitive decline and shorter survival times. The ɛ4 allele has also been linked to the severity of hippocampal atrophy and pathological alterations in the neocortex. The ɛ2 allele is thought to exert protection against the disease.
“Atrophy of the hippocampus, a region of the brain crucial for memory, is a common feature of AD, although it may also be detected in asymptomatic individuals as well as healthy adult carriers of the ApoE ɛ4 allele,” explained Andy Simmons, PhD, of the Department of Neuroimaging of the Institute of Psychiatry of King’s College London. “Whether young people genetically at risk for AD manifest early changes is an important question for those interested in interventions or treatments designed to slow or stop the progression of the disease.”
To address the question, 1412 adolescents underwent MRI imaging and had blood samples tested for DNA analysis in order to determine their ApoE status. “Contrary to some recent studies, no hippocampal volume differences were observed between carriers and non-carriers of the ApoE ɛ4 allelle,” said Dr. Simmons. The investigators also looked for other potential changes, such as hippocampal asymmetry or gene dose-dependent effects on volume, but could find no associations with genetic status.
In addition to structural changes in the brain, patients with AD typically show an increase in the brain load of amyloid-β (Aβ) peptides and a decrease in cerebrospinal fluid (CSF) concentration of Aβ peptides. Similar changes are found in almost all persons with mild cognitive impairment at risk of conversion to AD. “These changes represent the earliest diagnostic tools in AD,” explains Professor Dr. med. Piotr Lewczuk, head of the Lab for Clinical Neurochemistry and Neurochemical Dementia Diagnostics, at the Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg. Since to some extent alterations of the concentrations of Aβ peptides are also observed in the blood, his research group explored differences in plasma levels of Aβ peptides among young adult ε4, ε3 or ε2 carriers.
To see whether these changes associated with AD are present at an early age, before clinical symptoms are apparent, investigators measured Aβ peptide concentrations in the plasma of 175 cognitively normal young adults. 40 individuals (22.9%) had at least one ε4 allele and were considered “at risk” for AD, 111 (63.4%) had the ε3/ε3 genotype and were considered “neutral,” and 24 (13.7%) in the “protective: group had at least one ε2 allele.
The investigators measured four Aβ peptides and found that no significant differences in plasma levels of any of the Aβ peptides were found among the three genetic groups.
“The lack of differences of the Aβ concentrations reported in this study between the groups with and without increased genetic risk of AD does not mean that ongoing pre-clinical neurodegeneration can be fully excluded in all young subjects,” says Dr. Lewczuk. He also notes that around 40% of AD patients are not carriers of the ε4 allele. However, he believes that both Dr. Simmons’ findings concerning hippocampal volume and his study on plasma Aβ concentrations suggest that the AD-suggestive alterations begin perhaps 20-30 years before the onset of clinical symptoms, but most probably not earlier.
# # #
NOTES FOR EDITORS
No Differences in Hippocampal Volume between Carriers and Non-Carriers of the ApoE ε4 and ε2 Alleles in Young Healthy Adolescents. Wasim Khan, Vincent Giampietro, Cedric Ginestet, Flavio Dell’Acqua, David Bouls, Steven Newhouse, Richard Dobson, Tobias Banaschewski, Gareth J. Barker, Arun L.W. Bokde, Christian Büchel , Patricia Conrod, Herta Flor, Vincent Frouin, Hugh Garavan, Penny Gowland, Anreas Heinz, Bernd Ittermann, Hervé Lemaîitre, Frauke Nees, Tomas Paus, Zdenka Pausova, Marcella Rietschel, Michael N. Smolka, Andreas Ströhleh, Jean Gallinat, Eric Westman, Gunther Schumann, Simon Lovestone, Andrew Simmons, and the IMAGEN consortium (www.imagen-europe.com). Journal of Alzheimer’s Disease, Volume 40/Issue 1 (March 2014). DOI: 10.3233/JAD-131841.
Reporters who wish to speak to the authors should contact Seil Collins, Press Officer, Institute of Psychiatry, King’s College London, at +44 207 848 5377, +44 0771 8697 176 (mobile) or firstname.lastname@example.org.
Plasma Concentrations of the Amyloid-β Peptides in Young Volunteers: The Influence of the APOE Genotype. Ruediger Zimmermann, Ellen Huber, Christine Schamber, Natalia Lelental, Barbara Mroczko, Sebastian Brandner, Juan Manuel Maler, Timo Oberstein, Maciej Szmitkowski, Manfred Rauh, Johannes Kornhuber and Piotr Lewczuk. Journal of Alzheimer’s Disease, published online ahead of issue, Volume 40/Issue 4 (May 2014). DOI: 10.3233/JAD-132687.
Reporters who wish to interview Prof. Dr. med. Piotr Lewczuk may contact him at the Lab for Clinical Neurochemistry and Neurochemical Dementia Diagnostics, Department of Psychiatry and Psychotherapy, at +49-(0)-9131-85 34324 or Piotr.Lewczuk@uk-erlangen.de.
ABOUT THE JOURNAL OF ALZHEIMER’S DISEASE (JAD)
The Journal of Alzheimer’s Disease is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer’s disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease and clinical trial outcomes. The Journal of Alzheimer’s Disease has an Impact Factor of 4.17 according to Thomson Reuters’ 2012 Journal Citation Reports. It is ranked #22 on the Index Copernicus Top 100 Journal List. The Journal is published by IOS Press.
ABOUT IOS PRESS
Commencing its publishing activities in 1987, IOS Press serves the information needs of scientific and medical communities worldwide. IOS Press now (co-)publishes over 100 international journals and about 90 book titles each year on subjects ranging from computer sciences and mathematics to medicine and the natural sciences.
IOS Press continues its rapid growth, embracing new technologies for the timely dissemination of information. All journals are available electronically and an e-book platform was launched in 2005.
Headquartered in Amsterdam with satellite offices in the USA, Germany, India and China, IOS Press has established several strategic co-publishing initiatives. Notable acquisitions included Delft University Press in 2005 and Millpress Science Publishers in 2008.